Laxmi Dental Ltd - Q1 FY27 Earnings Call Summary Wednesday, August 12, 2026 11:00 AM IST
Event Participants
Executives
2
Sameer Merchant (Managing Director and CEO), Dharmesh Dattani (Chief Financial Officer)
Analysts
8
Anchit Jalan (Goldman Sachs), Archit (Rockstar Equity Research), Devanshi Shah (HUF Capital), Hetvi Sanghvi (HS Investments), Meet Mehta (Prasun Exposures), Priya Kulkarni (CM Capital), Rishikesh Raj Singh (Individual Investor), Unidentified (Motilal Oswal Financial Services)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹74.7 crores | +13.9% YoY (highest ever quarterly revenue) |
| Gross Profit | ₹58.7 crores | +22.1% YoY; gross margin improved to 78.6% |
| Segment Revenue - Dental Lab | ₹48.5 crores | +23.5% YoY, driven by strong domestic and international performance |
| Segment Revenue - International Dental Lab | — | +37.4% YoY, led by US DSO relationships and existing retail business; ~10-12% currency tailwind |
| Segment Revenue - Aligner Solutions | — | +28.6% YoY; segment business grew 27.8% and media 29.3% |
| Segment Revenue - Kidzee Dental (Pediatric) | — | +54.4% YoY, steadily scaling up |
| Domestic Dental Lab (ex-scanners) | — | ~12% growth, expected to accelerate from Q2 onwards |
| EBITDA | ₹14.4 crores | +20.6% YoY (highest ever); margin 19.2% vs 18.0% YoY and ~15% QoQ |
| Adjusted EBITDA | ₹16.0 crores | Vs ₹14.8 crore YoY; includes 60% of Laxmi Dental Ltd PAT, 49% of IDBG AI Dent Ltd PAT, ESOP expenses |
| PAT | ₹10.3 crores | +23.8% YoY; PAT margin 13.8% |
| Employee Cost | ₹28.4 crores | +6.2% sequentially; due to US CEO appointment and sales/ops additions |
| ESOP Expenses | ₹83 lakhs | Nearly half of last year's level |
| Other Expenses | ₹15.9 crores | Vs ₹12.5 crore YoY; higher freight, ECL provisions, AI-led automation spend |
| Finance Cost | ₹0.3 crores | Company remains debt-free |
| Scanner Deployment Target (FY27) | 800–1,000 units | On track; average scanner price ~₹3 lakh |
| Digital Penetration (Domestic) | 75–80% | International is majority digital; industry scanner adoption ~7–8% |
| Capacity Utilization - Aligners | ~70% | Remaining headroom for automation-driven scaling |
| Capacity Utilization - Lab | ~90–95% | Custom manufacturing; running at near-full threshold |
Geographic & Segment Commentary
Dental Lab (Domestic): Grew ~12% ex-scanners, slower than international but management expects upward momentum through Q2–Q4 as scanner deployments mature. Satellite lab strategy brings the company closer to customers; management sees this as a near-term growth lever.
Dental Lab (International): Grew 37.4% YoY, with USD appreciation (~85→95, ~10-12%) contributing. New US-based CEO with 32 years of medical devices/dental experience appointed to drive market-focused strategy. Company will participate in the International Dental Show (IDS) later in FY27 to expand global distributor network. New geographies are being added to pilot phase every quarter.
Aligner Solutions: Grew 28.6% YoY, driven by education/training programs, iScope at-home aligner monitoring launch, and 2-3 additional product launches planned in coming quarters. Distribution strictly through dentists (no B2C). General dentists are a growing channel globally as aligners become mainstream.
Pediatric Dentistry (Kidzee Dental): Grew 54.4% YoY, scaling steadily. Reflects early penetration in a specialized dental segment.
Company-Specific & Strategic Commentary
Capacity Expansion / Facility Ownership: Executed LOI to acquire land in Palghar, Maharashtra, to transition from two leased facilities (current rent ~₹2 crore/year) to a single owned facility ~3x the current size. This is expected to reduce rental cost exposure long-term (future 3x scale would imply ₹5-6 crore/year in rent) and enable operational efficiency. Phased transition planned with minimal disruption due to digital workflows.
Digitalization & Scanners: Scanner deployment run-rate of 800–1,000 units targeted for FY27 at ~₹3 lakh average price. Scanners act as a gateway to digital dentistry; current industry adoption is only ~7–8%, providing significant headroom. Gestation period from scanner sale to business conversion is 6–18 months, with domestic lab growth expected to benefit from Q2–Q4 FY27.
AI & Automation: Investing in AI-led automation initiatives, including AI crowns already in beta. Current costs are elevated during the pilot phase but expected to reduce meaningfully next year as scale kicks in. These initiatives are central to improving workflow efficiency and long-term margins.
Brand Building: Launched brand ambassador (Kareena Kapoor), in-clinic branding, social media advertising, and patient education campaigns. Positioning as the only branded player in the crown category; management views branding as a 3–10 year structural differentiator.
ESOP Normalization: ESOP costs (~₹83 lakhs) are now roughly half of prior year levels, removing a headwind that had compressed FY26 EBITDA margin to 15.6%.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | 15–20% for FY27 | Management reiterated aspiration; Q1 delivered 13.9% partly due to scanner mix; expects acceleration in H2 |
| EBITDA Margin | 18–20% for FY27 | Q1 at 19.2%; normalizing ESOP costs and margin expansion from favorable mix support the range; labors code, tariffs and one-offs that depressed FY26 (15.6%) are behind |
| Domestic Lab Growth | Accelerating from Q2–Q4 FY27 | Scanner deployments maturing after 6–18 month gestation; satellite lab expansion adds momentum |
| Aligner Growth | Sustained momentum | New product launches (2-3 in pipeline), iScope monitoring, education/training programs |
| Gross Margins | Stable ex-scanner fluctuations | Scanner is a low-margin trading item (15–20% gross); strong scanner quarters will create gross margin dips but drive future recurring business |
| Facility Transition | Phased move to Palghar | No revenue or productivity disruption expected due to digital-first manufacturing |
Risks & Constraints
| Risk | Context |
|---|---|
| Scanner Mix Impact on Margins | Scanners carry only 15–20% gross margin; high scanner sales quarters can compress reported gross/EBITDA margins, creating quarterly lumpiness. Management frames this as a deliberate digital-enablement investment for recurring future business. |
| Currency-Dependent International Growth | ~10–12% of the 37.4% international growth came from USD appreciation (85→95). As base effects normalize, constant-currency growth will be the true indicator; management acknowledges forex arbitrage may not persist. |
| Competitive Pressure in Online/Aligners | Online competition remains present and persistent. Management's counter-strategy relies on 36 years of brand trust, cross-selling to existing dentist customers, and continued innovation. |
| Capacity Constraints in Lab Business | Labs run at 90–95% capacity utilization; any demand surge requires automation/digitization investments (in progress) or the Palghar facility expansion to come online. |
| Transition Risk on Facility Move | Moving from two leased Mumbai facilities to a new owned Palghar campus carries execution risk. Management states digital workflows minimize disruption but did not provide a detailed timeline. |
| Share Price Underperformance | Stock has declined from ₹500 (Jan 2025) to ~₹200 despite strong results. Management highlighted that it purchased shares near ₹200 and remains bullish, but external sentiment factors are beyond control. |
Q&A Highlights
Scanner Differentiation & Business Model
- Question: What makes dentists choose Laxmi Dental after using the iScan Pro scanner, and what distinguishes it from competitors? (Meet Mehta, Prasun Exposures)
- Answer: Three core pillars — 36-year track record building trust (dentists who placed crowns 36 years ago), global quality standards (ISO-certified processes, consistent output), and innovation/branding (only branded player in crown category). (Sameer Merchant)
Scanner Margins & Digitization
- Question: What is the gross margin on scanners, and should margins be lumpy going forward? (Meet Mehta)
- Answer: Scanners are trading items with a normal 15–20% gross margin. Ex-scanner margins are stable and rising; Q1 EBITDA margin improved to 19.2% vs 15% QoQ and 18% YoY. Minor quarterly fluctuations from scanner mix are expected and acceptable as part of digital dentistry enablement. (Sameer Merchant)
Capacity Utilization
- Question: What is current capacity utilization in lab and aligner businesses? (Meet Mehta)
- Answer: Aligners ~70% — has automation headroom. Labs ~90–95% — heavily custom, less automated; automation/digitization investments are aimed at addressing this. (Sameer Merchant)
Palghar Land Acquisition & Rent Rationalization
- Question: What is the land parcel for, and what kind of disruption should be expected? (Anchit Jalan, Goldman Sachs)
- Answer: Currently paying ~₹2 crore/year in rent for two leased facilities (Illusion Dental + Aligners). New owned facility in Palghar will be ~3x current size, allowing future expansion without paying ₹5–6 crore in rental. Transition will be phased with zero revenue/productivity disruption because operations are digital-first. (Sameer Merchant)
US CEO Appointment & AI Investments
- Question: Was the US CEO hired due to visible traction, and can you expand on AI-led expenses? (Anchit Jalan)
- Answer: CEO brings 32 years of industry experience with dental connect. Specific contribution discussed one-on-one. AI crowns are in beta — initial costs are higher but will decline materially next year as scale builds. Margin guidance of 19.2% this quarter could sustain or improve through the year. (Sameer Merchant)
International Growth — Constant Currency vs Forex
- Question: What's the constant-currency growth and currency benefit split? (Unidentified, Motilal Oswal)
- Answer: USD moved
85 to ~95 (12% YoY tailwind). International business grew 37.4% — even after stripping ~10-12% currency effect, constant-currency growth is ~25%+. Forex arbitrage may not persist; underlying growth remains strong. (Sameer Merchant)
Aligner Growth Drivers & Target Market
- Question: What is driving aligner growth, and are you targeting general dentists vs orthodontists? (Hetvi Sanghvi, HS Investments; Unidentified, Motilal Oswal)
- Answer: Growth driven by education/training programs and iScope launch (home aligner monitoring), with 2-3 new launches in pipeline. No B2C — distribution exclusively through dentists. No differentiation between orthodontists and general dentists; globally, general dentists are contributing growing aligner revenue as education improves confidence. (Sameer Merchant)
Scanner Deployment & FY27 Guidance
- Question: How many scanners planned for deployment, and what does EBITDA guidance look like? (Anchit Jalan, Goldman Sachs)
- Answer: 800–1,000 scanners for FY27 at ~₹3 lakh average — still on track. Revenue growth aspiration 15–20% and EBITDA margin 18–20%. FY26 was impacted by labor code, tariffs, and elevated ESOP costs (now halved) — hence normalization supports the higher range this year. (Sameer Merchant)
Share Price Declines Despite Strong Results
- Question: Stock fell from ~₹500 (Jan 2025) to ~₹200; market seems unimpressed — what's being missed? (Individual investor)
- Answer: Performance is the only controllable. Management bought shares near ₹200 and will continue buying when liquidity permits. Dental awareness is only rising globally; the next 5–10 years are viewed with strong optimism. (Sameer Merchant)
Brand Building & Competitive Positioning
- Question: What initiatives are underway to build a brand in the dental industry? (Devanshi Shah, HUF Capital)
- Answer: Brand ambassadors (Kareena Kapoor), in-clinic branding, social media advertising, and patient education driving "ask your dentist for the right restoration." Branding is a long-term play expected to become a top differentiator in 3–10 years. (Sameer Merchant)
Aligners — Industry vs Out-of-Industry Growth
- Question: Industry is growing ~30% CAGR; you grew 29% YoY. Do you plan to merely match or outgrow the industry? (Archit, Rockstar Equity Research)
- Answer: Goal is to outgrow the industry. Efforts include brand ambassador campaigns, aligner education, dentist training, and patient-facing social media marketing — pointed toward building one of India's strongest aligner brands in 3–5 years. (Sameer Merchant)
Key Takeaway
Laxmi Dental delivered its highest-ever quarterly revenue (₹74.7 crores, +13.9% YoY) with EBITDA up 20.6% to ₹14.4 crores (19.2% margin) and PAT up 23.8% to ₹10.3 crores (13.8% margin) — all driven by favorable product mix, normalized ESOP costs, and broad-based segment growth led by international dental labs (+37.4% YoY), aligners (+28.6%), and pediatric dentistry (+54.4%). Strategic priorities include deploying 800–1,000 intraoral scanners as a digital onboarding gateway, investing in AI crown automation (currently in beta), appointing a US-based CEO to scale the most critical international market, and transitioning from leased Mumbai facilities to an owned 3x-larger Palghar campus to structurally reduce rent. Management reiterated FY27 guidance of 15–20% revenue growth and 18–20% EBITDA margins, backed by maturing scanner-driven domestic growth acceleration expected from Q2 onwards. Key watch points: scanner mix-driven quarterly margin fluctuation, currency tailwind normalization in international revenue, successful facility transition execution, and share price (down ~60% from IPO levels despite results) — with management actively buying shares near current levels as a conviction signal. The company remains debt-free with finance costs of just ₹0.3 crores, positioning it to self-fund the planned capacity expansion and automation investments.